CEL-SCI Shares Are Trading Higher After the Company Announced It Received FDA Approval for Its Confirmatory Study of Multikine for the Treatment of Head & Neck Cancer.
CEL-SCI Shares Are Trading Higher After the Company Announced It Received FDA Approval for Its Confirmatory Study of Multikine for the Treatment of Head & Neck Cancer.
CEL-SCI宣佈其用於治療頭頸癌的Multikine的確認性研究獲得美國食品藥品管理局批准後，該公司股價走高。
CEL-SCI Shares Are Trading Higher After the Company Announced It Received FDA Approval for Its Confirmatory Study of Multikine for the Treatment of Head & Neck Cancer.
CEL-SCI宣佈其用於治療頭頸癌的Multikine的確認性研究獲得美國食品藥品管理局批准後，該公司股價走高。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。